Primary Immunodeficiency Diseases Market (By Disease: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder; By Test: Blood Test and Prenatal Testing; By Treatment: Immunoglobulin Replacement Therapy, Antibiotics Therapy, Stem cell and Gene Therapy and Others; By Geography: North America, Europe, Asia Pacific, and Rest of the World) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Primary Immunodeficiency Diseases Market (By Disease: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder; By Test: Blood Test and Prenatal Testing; By Treatment: Immunoglobulin Replacement Therapy, Antibiotics Therapy, Stem cell and Gene Therapy and Others; By Geography: North America, Europe, Asia Pacific, and Rest of the World) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Nov 2015 Transparency Market Research Antibiotics117 Pages Price :
$ 5795

This report on the primary immunodeficiency diseases (PIDD) market studies the current as well as future prospects of the market. The stakeholders of this report include pharmaceuticals companies, diagnostic kits providers, distributors, care providers and insurance companies (payers) and other intermediaries engaged in PIDD as well as new entrants that are planning to enter in this segment. This report comprises an elaborate executive summary with a market snapshot providing overall information of various segments and sub-segments considered in the study scope. The executive summary also provides overall information and data analysis of the PIDD market with respect to the leading market segments based on Disease, Test, Treatment and Geography. The market revenue in terms of USD million for the period between 2013 and 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all segments and sub-segments considered under the scope of study, considering 2014 as the base year. Pipeline analysis (qualitative) for Phase I, II candidates whereas a detailed quantitative aspect (US$ Mn) for III drugs are illustrated in the market overview chapter.

The report analyzed the PIDD market from four prominent segments: by Disease, by Test, by Treatment and by Geography. In terms of market by disease the overall market is segmented into three broad categories: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder. The antibody deficiency market is further analyzed and estimated for Agammaglobulinaemia, Common Variable Immune Deficiency, Selective IgA Deficiency, IgG Subclass Deficiency and Others. Whereas, cellular immunodeficiency market is sub-segmented into Ataxia Telangiectasia, Hyper IgM Syndromes, Wiskott-Aldrich Syndrome, DiGeorge Syndrome and Others. The innate immune disorder market include Complement Deficiencies, Hyper IgE Syndrome and Others. Moreover this report also studies the global market by test for diagnosis which encompasses blood test and prenatal testing. The global PIDD market by treatment include both qualitative and quantitative analysis for immunoglobulin replacement therapy, antibiotics therapy, stem cell and gene therapy and others.

Geographically the market is divided into four major regions: North America, Europe, Asia Pacific and Rest of the World. The North America market incorporates The United States and Canada. The Europe region is accessed for Germany, United Kingdom and Rest of Europe. The Asia Pacific (APAC) market is sub-segmented into India, China and Rest of APAC. Rest of the World (RoW) include Latin America, Middle East and North Africa and Rest of RoW

Each of the aforementioned segments has been analyzed in detail for market trends, recent developments, outlook, and opportunities. The market overview section of the report explores market dynamics such as drivers, restraints, and opportunities that currently have strong impact on the global PIDD market which could influence the market in the future as well. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition between leading market players in the U.S. market. Porter

Table of Contents

1. Introduction
1.1. Report Description
1.2. Research Methodology 
1.3. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Primary Immunodeficiency Diseases Market, 2014 and 2023E
2.2. Global Primary Immunodeficiency Diseases Market Revenue, by Disease, 2014 (US$ Mn)
2.3. Global Primary Immunodeficiency Diseases Market Revenue, by Subclass Disease, 2014 (US$ Mn)
2.4. Global Primary Immunodeficiency Diseases Market Revenue, by Test, 2014 (US$ Mn)
2.5. Global Primary Immunodeficiency Diseases Market Revenue, by Treatment, 2014 (US$ Mn)
2.6. Comparative Analysis: Global Primary Immunodeficiency Diseases Market, by Geography 2014 & 2023 (Value %)

3. Market Overview
3.1. Market Dynamics
3.2. Drivers
3.2.1. Government approval of new therapies for the PIDD treatment 
3.2.2. Gradual increase in the incidence of primary immunodeficiency diseases globally
3.2.3. Rising awareness campaigns drive demand for PIDD therapeutics or therapy
3.3. Restraints
3.3.1. Lack of Adequate Reimbursement and High Treatment Cost Hindering PIDD Market Growth
3.3.2. Rising Number of Undiagnosed Patients Affecting Revenue Inflow
3.4. Opportunities
3.4.1. New Born Screening in Emerging Markets Expected to Provide New Opportunities
3.5. Porter’s Five Forces Analysis, Global Primary Immunodeficiency Diseases Market
3.6. Market Attractiveness Analysis, by Geography
3.7. Competitive Landscape (Market Share Analysis), by Key Players
3.8. Pipeline Analysis (Phase I and Phase II): Immunoglobulins
3.9. Pipeline Analysis: (Phase III): Immunoglobulins (US$ Mn)

4. Primary Immunodeficiency Diseases Market, by Disease
4.1. Introduction
4.2. Antibody Deficiency
4.2.1. Global Agammaglobulinaemia Market Revenue, 2013–2023, (US$ Mn)
4.2.2. Global Common Variable Immune Deficiency Market Revenue, 2013–2023, (US$ Mn)
4.2.3. Global Selective IgA Deficiency (SIgAD) Market Revenue, 2013–2023, (US$ Mn)
4.2.4. Global IgG Subclass Deficiency Market Revenue, 2013–2023, (US$ Mn)
4.2.5. Global Other Antibody Deficiency Market Revenue, 2013–2023, (US$ Mn)
4.3. Cellular Immunodeficiency
4.3.1. Global Ataxia Telangiectasia Market Revenue, 2013–2023, (US$ Mn)
4.3.2. Global Hyper IgM Syndromes Market Revenue, 2013–2023, (US$ Mn)
4.3.3. Global Wiskott-Aldrich Syndrome Market Revenue, 2013–2023, (US$ Mn)
4.3.4. Global DiGeorge Syndrome Market Revenue, 2013–2023, (US$ Mn)
4.3.5. Global Other Cellular Immunodeficiency Market Revenue, 2013–2023, (US$ Mn)
4.4. Innate Immune Disorder
4.4.1. Global Complement Deficiencies Market Revenue, 2013–2023, (US$ Mn)
4.4.2. Global Hyper IgE Syndrome Market Revenue, 2013–2023, (US$ Mn)
4.4.3. Global Other Innate Immune Disorder Market Revenue, 2013–2023, (US$ Mn)

5. Primary Immunodeficiency Diseases Market, by Test
5.1. Introduction
5.2. Global Primary Immunodeficiency Diseases Market Revenue, by Blood Test, 2013–2023 (US$ Mn)
5.3. Global Primary Immunodeficiency Diseases Market Revenue, by Prenatal Testing, 2013–2023 (US$ Mn)

6. Primary Immunodeficiency Diseases Market, by Treatment
6.1. Introduction
6.2. Global Immunoglobulin Replacement Therapy Market Revenue, 2013–2023 (US$ Mn)
6.3. Global Antibiotics Therapy Market Revenue, 2013–2023, (US$ Mn)
6.4. Global Stem cell and Gene Therapy Market Revenue, 2013–2023, (US$ Mn)
6.5. Global Other Primary Immunodeficiency Disease Treatments Market Revenue, 2013–2023, (US$ Mn)

7. Primary Immunodeficiency Diseases Market, by Geography
7.1. Introduction
7.2. North America Primary Immunodeficiency Diseases Market Revenue, by Country, 2013–2023 (US$ Mn)
7.3. Europe Primary Immunodeficiency Diseases Market, by Country, 2013–2023 (US$ Mn)
7.4. Asia Pacific Primary Immunodeficiency Diseases Market Revenue, by Country, 2013–2023 (US$ Mn)
7.5. Rest of the World Primary Immunodeficiency Diseases Market Revenue, by Country, 2013–2023 (US$ Mn)

8. Recommendations
 

9. Company Profiles
9.1. Baxter International, Inc.
9.2. Biotest AG
9.3. CSL Behring LLC
9.4. Bio Products Laboratory Ltd.
9.5. Kedrion S.p.A.
9.6. LFB S.A.
9.7. Octapharma AG
9.8. Grifols S.A.

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 5795
$ 8795

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top